SENTI BIOSCIENCES INC (SNTI)
US81726A1007 - Common Stock
Overall SNTI gets a fundamental rating of 3 out of 10. We evaluated SNTI against 561 industry peers in the Biotechnology industry. While SNTI seems to be doing ok healthwise, there are quite some concerns on its profitability. SNTI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SNTI has reported negative net income.
In the past year SNTI has reported a negative cash flow from operations.
SNTI had negative earnings in each of the past 5 years.
In the past 5 years SNTI always reported negative operating cash flow.
1.2 Ratios
SNTI's Return On Assets of -122.83% is on the low side compared to the rest of the industry. SNTI is outperformed by 80.72% of its industry peers.
SNTI has a worse Return On Equity (-443.27%) than 78.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.83% | ||
| ROE | -443.27% | ||
| ROIC | N/A |
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNTI has been reduced compared to 1 year ago.
SNTI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -10.36, we must say that SNTI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.36, SNTI is doing worse than 75.32% of the companies in the same industry.
SNTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.36 |
ROIC/WACCN/A
WACC10.66%
2.3 Liquidity
A Current Ratio of 1.92 indicates that SNTI should not have too much problems paying its short term obligations.
With a Current ratio value of 1.92, SNTI is not doing good in the industry: 77.12% of the companies in the same industry are doing better.
SNTI has a Quick Ratio of 1.92. This is a normal value and indicates that SNTI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SNTI (1.92) is worse than 75.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
The earnings per share for SNTI have decreased strongly by -893.05% in the last year.
Looking at the last year, SNTI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
SNTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 65.01% yearly.
EPS 1Y (TTM)-893.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1811.08%
Revenue 1Y (TTM)-100%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
SNTI is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.73% yearly.
The Revenue is expected to grow by 67.25% on average over the next years. This is a very strong growth
EPS Next Y-848.26%
EPS Next 2Y-10.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year21.74%
Revenue Next 2Y47.44%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SNTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as SNTI's earnings are expected to decrease with -10.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.73%
EPS Next 3YN/A
5. Dividend
5.1 Amount
SNTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SENTI BIOSCIENCES INC
NASDAQ:SNTI (1/10/2025, 9:41:58 AM)
3.82
-0.08 (-2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.64%
Inst Owner Change0%
Ins Owners3.91%
Ins Owner Change0%
Market Cap17.53M
Analysts82.86
Price Target12.24 (220.42%)
Short Float %2.87%
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)100%
PT rev (3m)100%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1825.83%
EPS NY rev (3m)-1825.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-68.54%
Revenue NY rev (3m)-68.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.1 | ||
| P/tB | 1.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-15.59
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-7.61
FCFYN/A
OCF(TTM)-7.61
OCFYN/A
SpS0
BVpS3.48
TBVpS3.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.83% | ||
| ROE | -443.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-49.62%
ROA(5y)-49.82%
ROE(3y)-81.17%
ROE(5y)-85.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.59% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z | -10.36 |
F-Score2
WACC10.66%
ROIC/WACCN/A
Cap/Depr(3y)1337.51%
Cap/Depr(5y)936.96%
Cap/Sales(3y)545.04%
Cap/Sales(5y)812.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-893.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1811.08%
EPS Next Y-848.26%
EPS Next 2Y-10.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y65.01%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year21.74%
Revenue Next 2Y47.44%
Revenue Next 3Y18.22%
Revenue Next 5Y67.25%
EBIT growth 1Y18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.77%
OCF growth 3YN/A
OCF growth 5YN/A